Lanxness took a majority stake in Evocatal, and joined existing investors including High-Tech Gruenderfonds in backing the enzymes producer.
Germany-based enzyme developer Evocatal has secured €3.5m ($4.5m) of series B funding from investors including financial services firm NRW.Bank and chemical producer Lanxness, the latter of which took a majority stake in the company.
LAnxness and NRW were joined byall the company’s existing investors, including corporate-backed venture fund High-Tech Gruenderfonds (HTGF) and venture capital firm Sirius Venture Partners.
Evocatal creates bespoke bio-catalysts for products from cosmetics to adhesives. The new funding will be used to extend its product range.
The…
